Matthew Luchini
Stock Analyst at BMO Capital
(2.05)
# 3,038
Out of 5,150 analysts
35
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $7.25 | +313.79% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.42 | +13,280.28% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $19.86 | +247.43% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $26.84 | +287.48% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $3.09 | +1,679.94% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $13.76 | +634.01% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $787.50 | -20.00% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $434.80 | -71.48% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $148.22 | -56.82% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $32.14 | -56.44% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.14 | +5,163.16% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $28 → $14 | $13.51 | +3.63% | 1 | Aug 15, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $7.25
Upside: +313.79%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.42
Upside: +13,280.28%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $19.86
Upside: +247.43%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $26.84
Upside: +287.48%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $3.09
Upside: +1,679.94%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $13.76
Upside: +634.01%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $787.50
Upside: -20.00%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $434.80
Upside: -71.48%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $148.22
Upside: -56.82%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $32.14
Upside: -56.44%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.14
Upside: +5,163.16%
Aug 15, 2018
Maintains: Market Perform
Price Target: $28 → $14
Current: $13.51
Upside: +3.63%